DUESSELDORF, Germany--(BUSINESS WIRE)--miacom diagnostics GmbH today announced that their proprietary hemoFISH
assay for the identification and differentiation of bacterial pathogens
from positive blood culture bottles is now commercially available in
Canada. The hemoFISH assays are the first Health Canada approved tests
out of miacoms´ diagnostic portfolio.
In cooperation with Nova
Century Scientific as a distributor, Canada is the first country on the
North American continent to have this rapid test. Nova Century
Scientific is a leader in the manufacture and distribution of diagnostic
kits and laboratory supplies for hospitals, clinical laboratories and
research institutions across Canada.
“We are happy to provide a new reliable tool for the rapid diagnostic of pathogens from blood cultures to our customers here in Canada. At NCS, our mission is customer satisfaction,” said Walter Schmidt, CEO Nova Century Scientific, “We are a company committed to meeting customer requirements and enhancing customer satisfaction through continual improvement of its products, services, and the quality of management.” Nova Century Scientific supports its broad range of quality laboratory products with personalized customer service and responsive technical support.
One of the first hospitals in Canada to use the new rapid test system is the Oakville Trafalgar Memorial Hospital, which is part of the Halton Healthcare Services. “Having a relatively simple, low capital cost test system that provides multiple pathogen identifications beyond the Gram stain within 30 minutes after a blood culture bottle turns positive may enable earlier directed antibiotic therapy even discontinuation (e.g. coagulase negative Staphylococcus). In conjunction with a local antibiogram, the organism ID should facilitate treatment decisions by an antibiotic stewardship team.” highlights Dr. Neil Rau, medical microbiologist and infectious diseases specialist.
The miacom assay combines a new way of sample handling with a specific optical marking of the pathogenic agents aiming for an identification and differentiation of various bacteria in 30 minutes. The assay can be easily implemented in nearly every laboratory since it does not require complicated hardware or special environment conditions.
“We´re proud to be able to offer practical solutions for special need by approved tests that are truly unique in the market”, said Dr. Mirko Stange, CEO of miacom diagnostics. For full diagnostic range the following products will be available: hemoFISH Gram (-) Panel (identification of Gram negative bacteria), hemoFISH Gram (+) Panel (identification of Gram positive bacteria), and hemoFISH Masterpanel (identification of Gram negative bacteria & Gram positive bacteria).
About miacom diagnostics (www.miacom-diagnostics.de)
Miacom diagnostics specializes in in vitro diagnostic
tests for pathogens causing acute systemic diseases. All kits enable a
simultaneous detection of clinically relevant pathogens directly from
specimens, and deliver results within 30 minutes. In Europe, Miacom has
already commercialized several rapid tests, including diagnostic tools
for important systemic infectious diseases such as sepsis and pneumonia.
All kits are designed as affordable multiplex tests that detect and
differentiate up to 14 bacterial targets on a single microscope slide.
